Efficacy of Etanercept in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis | Zendy

Sean Dreyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Etanercept in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Author(s) -

Sean Dreyer

Publication year - 2021

Publication title -

cutis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.289

H-Index - 53

eISSN - 2326-6929

pISSN - 0011-4162

DOI - 10.12788/cutis.0288

Subject(s) - medicine , toxic epidermal necrolysis , etanercept , dermatology , immunology , tumor necrosis factor alpha

It has been suggested that the use of etanercept for treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) might provide improved mortality benefit and decreased skin healing times. This retrospective study compared the use of single-dose subcutaneous etanercept to intravenous immunoglobulin (IVIG) and supportive care alone. Thirteen patients were treated with a single dose (50 mg) of subcutaneous etanercept. Results of this study support the use of etanercept as a potentially beneficial agent in the treatment of SJS/TEN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research